Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52

Clinical Colorectal Cancer

Volumn 11, Issue 1, 2012, Pages 31-37

  Bolton, John S ^a   O'Connell, Michael J ^b   Mahoney, Michelle R ^c   Farr, Gist H ^d   Fitch, Tom R ^e   Maples, William J ^f   Nagorney, David M ^c   Rubin, Joseph ^c   Fuloria, Jyotsna ^a   Steen, Preston D ^g   Alberts, Steven R ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NSABP Foundation Inc   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d Gibbs Cancer Center and Research Institute   (United States)

^e MAYO CLINIC   (United States)

^f MAYO CLINIC   (United States)

^g MeritCare Hospital   (United States)

Author keywords

Hepatic arterial infusion; NCCTG; Resected liver metastases; Systemic chemotherapy

Indexed keywords

ASPARTATE AMINOTRANSFERASE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; PHOSPHATE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT OBSTRUCTION; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHRONIC HEPATITIS; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; GASTRITIS; GASTROENTERITIS; HEPATIC ARTERY; HUMAN; INFECTION; LETHARGY; LIVER METASTASIS; LIVER RESECTION; MALE; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; STOMATITIS;

EID: 84861566481     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.03.029     Document Type: Article

References (29)

1. Steele GD Jr. The National Cancer Data Base Report on colorectal cancer. Cancer 1994; 74:1979-89.
2. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon cancer. N Engl J Med 1990; 322:352-58.
3. Cromheecke M, de Jong K, Hoekstra H. Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 1999; 25:451-63.
4. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-46.
5. Adson MA, Van Heerden JA. Major hepatic resections for metastatic colorectal cancer. Ann Surg 1980; 191:576-83.
6. Wilson SM, Adson MA. Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg 1976; 3:330-3.
7. Bismuth H, Krissat J, Adam R. Evidence for metastasectomy for colorectal liver metastases. In Cunningham D, Allen-Mersh T, Miles A, eds. The Effective Management of Metastatic Colorectal Cancer. London, UK: Aesculapius Medical Press; 1999:12-24.
8. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-53.
9. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999; 49:231-55.
10. Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a biinstitutional analysis. Ann Surg 2002; 235:863-71.
11. Fong Y, Blumgart LH. Hepatic colorectal metastasis: current status of surgical therapy. Oncol 1998; 12:1489-98.
12. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002; 20:1499-505.
13. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-48.
14. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994; 12:2288-95.
15. Martin JK, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic flurouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022-27.
16. O'Connell MJ, Nagorney DM, Bernath AM, et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998; 16:2528-33.
17. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional vs. systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685-93.
18. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107:459-65.
19. O'Connell MJ, Mailliard J, Nagorney DM, et al. Sequential intrahepatic 5-fluorodeoxyuridine (FUDR) and systemic 5-fluorouracil (5FU) +leucovorin (Lv) in patients with metastatic colorectal cancer (CRC) confined to the liver. Proc Am Soc Clin Oncol 1994; 13:219: abstract 662.
20. Hohn DC, Stagg RJ, Price DC, et al. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2'-deoxyuridine. J Clin Oncol 1985; 3:1257-60.
21. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53:457-81.
22. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352:734-5.
23. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery vs. surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228:756-62.
24. Lygidakis NJ, Ziras N, Parissis J. Resection vs. resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 1995; 142:155-61.
25. Rudroff C, Altendorf-Hoffmann A, Stangl R, et al. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 1999; 384:243-9.
26. Tono T, Hasuike Y, Ohzato H, et al. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: a randomized study. Cancer 2000; 88:1549-56.
27. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990; 8:1885-93.
28. Alberts SR, Roh MS, Mahoney MR, et al. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol 2010;28:853-8.
29. Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver.[update of Cochrane Database Syst Rev. 2004;(2):CD003770; PMID: 15106219]. Cochrane Database of Systematic Reviews 2006; 1-17.